Dyadic International Inc. (NASDAQ:DYAI) Short Interest Update

Dyadic International Inc. (NASDAQ:DYAI) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 52,977 shares, a decrease of 36.6% from the July 15th total of 83,534 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 212,919 shares, the short-interest ratio is currently 0.2 days.

Dyadic International Stock Down 1.1%

Dyadic International stock traded down $0.01 on Wednesday, hitting $0.76. 49,715 shares of the stock traded hands, compared to its average volume of 182,351. Dyadic International has a 1 year low of $0.65 and a 1 year high of $1.60. The firm has a market cap of $27.55 million, a P/E ratio of -3.29 and a beta of 1.12. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 4.08. The business’s fifty day simple moving average is $0.97 and its 200 day simple moving average is $0.86.

Dyadic International (NASDAQ:DYAI) last released its earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). Dyadic International had a negative return on equity of 2,920.31% and a negative net margin of 201.43%.The business had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $1.02 million. As a group, sell-side analysts forecast that Dyadic International will post 0.13 earnings per share for the current year.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Dyadic International has an average rating of “Hold” and an average target price of $3.00.

Hedge Funds Weigh In On Dyadic International

Several large investors have recently made changes to their positions in DYAI. Bank of America Corp DE boosted its position in shares of Dyadic International by 16,146.7% in the 4th quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. bought a new position in Dyadic International during the 2nd quarter valued at approximately $50,000. Marathon Capital Management raised its stake in Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after buying an additional 50,000 shares during the last quarter. BlackRock Inc. purchased a new position in Dyadic International during the second quarter valued at $177,000. Finally, Geode Capital Management LLC boosted its holdings in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock worth $284,000 after acquiring an additional 36,266 shares in the last quarter. 27.95% of the stock is currently owned by hedge funds and other institutional investors.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.